Phong Phu Pharmaceutical JSC (HNX:PPP)
Vietnam · Delayed Price · Currency is VND 21,600
+1,700 (8.54%)
At close: Sep 5, 2025
HNX:PPP Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 135,888 | 137,548 | 152,172 | 150,575 | 133,289 | 116,257 | Upgrade | |
Revenue Growth (YoY) | -5.23% | -9.61% | 1.06% | 12.97% | 14.65% | -23.28% | Upgrade |
Cost of Revenue | 87,403 | 91,144 | 103,016 | 99,285 | 88,053 | 80,245 | Upgrade |
Gross Profit | 48,485 | 46,404 | 49,156 | 51,290 | 45,237 | 36,012 | Upgrade |
Selling, General & Admin | 26,210 | 26,149 | 26,046 | 26,096 | 25,543 | 23,330 | Upgrade |
Operating Expenses | 26,210 | 26,149 | 26,046 | 26,096 | 25,543 | 23,330 | Upgrade |
Operating Income | 22,275 | 20,255 | 23,110 | 25,194 | 19,693 | 12,682 | Upgrade |
Interest Expense | -23.97 | - | - | -45.36 | -434.42 | -1,649 | Upgrade |
Interest & Investment Income | 1,511 | 1,390 | 1,327 | 561.01 | 109.53 | 187.27 | Upgrade |
Currency Exchange Gain (Loss) | -0.96 | -0.96 | -1.46 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | 82.64 | 143.82 | 150.99 | 93.21 | 77.97 | 332.1 | Upgrade |
EBT Excluding Unusual Items | 23,844 | 21,788 | 24,587 | 25,802 | 19,446 | 11,552 | Upgrade |
Gain (Loss) on Sale of Assets | 22.35 | 22.35 | 0.94 | - | - | - | Upgrade |
Pretax Income | 23,866 | 21,810 | 24,588 | 25,802 | 19,446 | 11,552 | Upgrade |
Income Tax Expense | 4,880 | 4,451 | 4,486 | 5,191 | 2,553 | 1,737 | Upgrade |
Net Income | 18,986 | 17,359 | 20,102 | 20,611 | 16,893 | 9,815 | Upgrade |
Preferred Dividends & Other Adjustments | 1,812 | 1,812 | 1,964 | - | - | - | Upgrade |
Net Income to Common | 17,175 | 15,548 | 18,138 | 20,611 | 16,893 | 9,815 | Upgrade |
Net Income Growth | 7.04% | -13.64% | -2.47% | 22.01% | 72.11% | -19.63% | Upgrade |
Shares Outstanding (Basic) | 9 | 9 | 9 | 10 | 10 | 10 | Upgrade |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 10 | 10 | 10 | Upgrade |
Shares Change (YoY) | -0.24% | - | -9.83% | -0.34% | -0.72% | 5.58% | Upgrade |
EPS (Basic) | 1948.42 | 1766.77 | 2061.13 | 2112.00 | 1725.00 | 995.00 | Upgrade |
EPS (Diluted) | 1948.42 | 1766.77 | 2061.13 | 2112.00 | 1725.00 | 995.00 | Upgrade |
EPS Growth | 9.15% | -14.28% | -2.41% | 22.43% | 73.37% | -23.87% | Upgrade |
Free Cash Flow | 13,520 | 16,787 | 17,428 | 20,117 | 18,129 | 9,045 | Upgrade |
Free Cash Flow Per Share | 1533.82 | 1907.56 | 1980.47 | 2061.38 | 1851.27 | 916.90 | Upgrade |
Dividend Per Share | 1500.000 | 1500.000 | 1200.000 | 1400.000 | - | - | Upgrade |
Dividend Growth | 25.00% | 25.00% | -14.29% | - | - | - | Upgrade |
Gross Margin | 35.68% | 33.74% | 32.30% | 34.06% | 33.94% | 30.98% | Upgrade |
Operating Margin | 16.39% | 14.73% | 15.19% | 16.73% | 14.77% | 10.91% | Upgrade |
Profit Margin | 12.64% | 11.30% | 11.92% | 13.69% | 12.67% | 8.44% | Upgrade |
Free Cash Flow Margin | 9.95% | 12.20% | 11.45% | 13.36% | 13.60% | 7.78% | Upgrade |
EBITDA | 26,323 | 24,368 | 27,926 | 31,419 | 25,871 | 18,878 | Upgrade |
EBITDA Margin | 19.37% | 17.72% | 18.35% | 20.87% | 19.41% | 16.24% | Upgrade |
D&A For EBITDA | 4,047 | 4,112 | 4,816 | 6,225 | 6,178 | 6,196 | Upgrade |
EBIT | 22,275 | 20,255 | 23,110 | 25,194 | 19,693 | 12,682 | Upgrade |
EBIT Margin | 16.39% | 14.73% | 15.19% | 16.73% | 14.77% | 10.91% | Upgrade |
Effective Tax Rate | 20.45% | 20.41% | 18.25% | 20.12% | 13.13% | 15.04% | Upgrade |
Revenue as Reported | 135,888 | 137,548 | 152,172 | 150,575 | 133,289 | 116,257 | Upgrade |
Advertising Expenses | - | 490.39 | 285.73 | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.